BioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8.6% Following Insider Selling
BioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8.6% Following Insider Selling
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating)'s share price traded down 8.6% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $29.82 and last traded at $29.93. 209,236 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 356,040 shares. The stock had previously closed at $32.73.
在一名內部人士拋售該公司股票後,BioXcel Treateutics,Inc.(納斯達克代碼:BTAI-GET Rating)的股價週三下跌8.6%。該公司股價最低跌至29.82美元,最新報29.93美元。209,236股午盤易手,較356,040股的平均成交量下跌41%。該股此前收盤報32.73美元。
Specifically, insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the insider now owns 8,397 shares in the company, valued at approximately $251,910. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Krishnan Nandabalan sold 27,450 shares of the business's stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $15.00, for a total transaction of $411,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Frank Yocca sold 50,000 shares of the business's stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the transaction, the insider now owns 8,397 shares of the company's stock, valued at approximately $251,910. The disclosure for this sale can be found here. Insiders sold a total of 133,339 shares of company stock worth $3,073,310 in the last quarter. 37.00% of the stock is owned by company insiders.
具體地説,內部人士Frank Yocca在1月20日星期五的一筆交易中出售了50,000股BioXcel治療公司的股票。這些股票以30.00美元的平均價格出售,總成交額為1500,000.00美元。出售完成後,這位內部人士現在擁有該公司8,397股,價值約251,910美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個環節。在相關新聞中,董事Krishnan Nandabalan在11月10日星期四的一筆交易中出售了27,450股該業務的股票。這些股票以15.00美元的平均價格出售,總成交金額為411,750.00美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過這個環節。此外,內部人士弗蘭克·約卡在1月20日星期五的一次交易中出售了50,000股該公司的股票。這些股票以30.00美元的平均價格出售,總成交額為1500,000.00美元。交易完成後,這位內部人士現在擁有該公司8,397股股票,價值約251,910美元。關於這次銷售的披露可以找到這裏。上個季度,內部人士總共出售了133,339股公司股票,價值3,073,310美元。37.00%的股份由公司內部人士持有。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of BioXcel Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a report on Tuesday, January 3rd. Mizuho lifted their price target on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research note on Thursday, December 15th. Canaccord Genuity Group lifted their price target on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research note on Friday, November 11th. Guggenheim cut their price target on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, November 11th. Finally, The Goldman Sachs Group raised shares of BioXcel Therapeutics from a "sell" rating to a "neutral" rating and set a $16.00 price target on the stock in a research note on Thursday, December 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $51.78.
一些研究分析師最近發佈了關於該股的報告。HC Wainwright將BioXcel治療公司的股票目標價從85.00美元下調至73.00美元,並在1月3日星期二的一份報告中為該公司設定了“買入”評級。瑞穗在12月15日星期四的一份研究報告中將BioXcel治療公司的股票目標價從18.00美元上調至24.00美元。11月11日,星期五,Canaccel Genuity Group將BioXcel治療公司的股票目標價從75.00美元上調至76.00美元,並在一份研究報告中給予該公司“買入”評級。11月11日,古根海姆將BioXcel治療公司的股票目標價從28.00美元下調至25.00美元,並在一份研究報告中對該股設定了“買入”評級。最後,高盛在12月1日(星期四)的一份研究報告中將BioXcel治療公司的股票評級從“賣出”上調至“中性”,併為該股設定了16.00美元的目標價。一位研究分析師對該股的評級為持有,七位分析師對該公司的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為“中等買入”,平均目標價為51.78美元.
BioXcel Therapeutics Stock Performance
BioXcel治療公司股票表現
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.15). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.05 million. As a group, equities analysts predict that BioXcel Therapeutics, Inc. will post -5.37 EPS for the current year.
BioXcel治療公司(納斯達克代碼:BTAI-GET Rating)上一次公佈季度收益數據是在11月10日星期四。該公司公佈了該季度每股收益(1.49美元),低於分析師普遍預期的(1.34美元)和(0.15美元)。該公司本季度營收為14萬美元,而分析師預期為305萬美元。作為一個整體,股票分析師預測BioXcel治療公司本年度將公佈每股收益5.37美元。
Institutional Trading of BioXcel Therapeutics
BioXcel治療公司的制度性交易
A number of institutional investors have recently made changes to their positions in BTAI. Point72 Hong Kong Ltd bought a new stake in shares of BioXcel Therapeutics in the second quarter worth $50,000. Quantbot Technologies LP acquired a new position in BioXcel Therapeutics during the third quarter worth $57,000. Amalgamated Bank acquired a new position in BioXcel Therapeutics during the first quarter worth $59,000. Game Plan Financial Advisors LLC acquired a new position in BioXcel Therapeutics during the second quarter worth $142,000. Finally, Virtus ETF Advisers LLC increased its holdings in BioXcel Therapeutics by 46.3% during the second quarter. Virtus ETF Advisers LLC now owns 11,284 shares of the company's stock worth $149,000 after buying an additional 3,571 shares during the last quarter. Institutional investors own 42.35% of the company's stock.
一些機構投資者最近改變了他們在BTAI的頭寸。Point72 Hong Kong Ltd在第二季度購買了BioXcel治療公司價值5萬美元的新股。Quantbot Technologies LP在第三季度收購了BioXcel治療公司的一個新頭寸,價值5.7萬美元。合併銀行在第一季度收購了BioXcel治療公司的一個新頭寸,價值59,000美元。遊戲計劃財務顧問公司在第二季度收購了BioXcel治療公司的一個新頭寸,價值14.2萬美元。最後,Virtus ETF Advisers LLC在第二季度將其在BioXcel治療公司的持股增加了46.3%。Virtus ETF Advisers LLC現在擁有11,284股該公司股票,價值149,000美元,上個季度又購買了3,571股。機構投資者持有該公司42.35%的股票。
About BioXcel Therapeutics
關於BioXcel治療公司
(Get Rating)
(獲取評級)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
BioXcel治療公司是一家商業階段的生物製藥公司,利用人工智能方法開發神經科學和免疫腫瘤學的變革性藥物。該公司的藥物再創新方法利用現有的批准藥物和/或臨牀驗證的候選產品,以及大數據和專有機器學習算法來識別新的治療指數。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- 免費獲取StockNews.com關於BioXcel治療(BTAI)的研究報告
- 兩大股利大王:強生還是雅培?
- 網絡安全類股已經見底了嗎?
- 聯合太平洋,諾福克南方進入購買區
- 柔順治療公司的差距增加了34%:未來還會有更多的好處嗎?
- 2023年初裁員將如何影響這5只生物科技股?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受BioXcel治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioXcel治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。